Post-transplant cyclophosphamide or cell selection in haploidentical allogeneic hematopoietic cell transplantation?
Razan MohtyZaid Al KadhimiMohamed A Kharfan-DabajaPublished in: Hematology (Amsterdam, Netherlands) (2024)
While acknowledging that no randomized controlled prospective studies have been yet conducted comparing TCD versus PTCy in haploidentical allo-HCT recipients, there are two advantages that would favor the PTCy, namely ease of application and lower cost. However, emerging data on adverse events associated with PTCy including, but not limited to cardiac associated toxicities or increased incidence of post-allograft infections, and others, are important to recognize.
Keyphrases
- stem cell transplantation
- high dose
- bone marrow
- kidney transplantation
- low dose
- double blind
- single cell
- open label
- risk factors
- peripheral blood
- left ventricular
- cell therapy
- electronic health record
- placebo controlled
- phase iii
- case control
- big data
- clinical trial
- heart failure
- cord blood
- stem cells
- cell cycle arrest
- atrial fibrillation
- signaling pathway
- study protocol